Form D · Biotechnology
Delphi Diagnostics Inc.
Houston, TX · CIK 0001695671
Offering snapshot reported Jun 21, 2021 · SEC filing
- Reported sold
- Yet to sell Offering amount: $50M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 21, 2021 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 26, 2017 | Initial | $470,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-403529
Source: Form D, filed Jun 21, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Winz Casagrande | Director, Executive |
| William Creech | Executive |
| Fidel Reijerse | Director |
| Paul Smith | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Tri Nguyen Law Office Pc 1220 Blalock Rd., Suite 300
Houston, TX, 77055
Houston, TX, 77055